Skip to main
ALT

Altimmune (ALT) Stock Forecast & Price Target

Altimmune (ALT) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Altimmune is poised for success in the near future as their lead asset, pemvidutide, has the potential to address multiple diseases with a differentiated approach. The recent preliminary data from the 48-week IMPACT trial, selected as a late-breaking oral presentation at EASL, is a positive indication of the company's progress. Their strong cash position and multiple catalysts in the near-term make them an attractive investment with potential for long-term success.

Bears say

Altimmune is burdened by heavy R&D and G&A expenses that continually outpace earnings, a reliance on equity raises to support clinical development and potential commercialization, and a high risk profile, including clinical development and competition risks. While the potential of their candidate pemvidutide may diversify the company's offerings and partnerships, the uncertainty of its success, coupled with potential setbacks from COVID-19 and a challenging market landscape, make it difficult to have confidence in the company's future profitability and potential to meet key data metrics.

Altimmune (ALT) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Altimmune and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Altimmune (ALT) Forecast

Analysts have given Altimmune (ALT) a Buy based on their latest research and market trends.

According to 4 analysts, Altimmune (ALT) has a Buy consensus rating as of Aug 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Altimmune (ALT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.